Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice
Parkinson's disease (PD) is a progressive neurological disorder estimated to affect 7-10 million people worldwide. There is no treatment available that cures or slows the progression of PD. Elevated leucine-rich repeat kinase 2 (LRRK2) activity has been associated with genetic and sporadic form...
Saved in:
Main Authors: | Joanna A. Korecka (Author), Ria Thomas (Author), Anthony J. Hinrich (Author), Alyssa M. Moskites (Author), Zach K. Macbain (Author), Penelope J. Hallett (Author), Ole Isacson (Author), Michelle L. Hastings (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2020-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model
by: Hien Tran Zhao, et al.
Published: (2017) -
LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model
by: Hien Tran Zhao, et al.
Published: (2021) -
LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model
by: Hien Tran Zhao, et al.
Published: (2021) -
A leucine‐rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls
by: Maurits F. J. M. Vissers, et al.
Published: (2023) -
LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives
by: Atashrazm F, et al.
Published: (2016)